Navigation Links
Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
Date:2/14/2012

LEXINGTON, Mass., Feb. 14, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today that the company completed its $4.1 million Series A angel-led financing.  Cherrystone Angels of Providence, Rhode Island led the round, with participation from Beacon Angels, Boston Harbor Angels, Launchpad Venture Group, Mass Medical Angels, North Country Angels and other individuals.

Dr. Barbara Fox, Avaxia's founder and CEO, commented, "This investment will allow us to pursue the development of our AVX-470 anti-TNF oral antibody and prepare Avaxia to start treating patients with inflammatory bowel disease in a clinical trial this coming fall.  In addition, the funding we have received from BARDA (Biomedical Advanced Research and Development Authority) to develop AVX-470 for GI Acute Radiation Syndrome provides Avaxia with resources to pursue products and value creation in two important disease areas.  Having broad support from the New England angel community demonstrates the important role that angels are playing in funding early stage biotech companies and provides Avaxia with an investor network for future funding."

The funds from this Series A financing will be used to manufacture the company's orally active anti-TNF for its upcoming clinical trial and to conduct final pre-clinical studies in advance of a Phase 1B clinical trial in patients with inflammatory bowel disease.  Prior to this equity round, the company raised $4.3 million in non-dilutive financing.   In addition to a loan from the Massachusetts Life Sciences Center and several SBIR grants, the company was awarded a $3.0 million, 2 year contract with BARDA that fully funds the initial research and development of an oral antibody therapy to mitigate the gastrointestinal damage that follows radiation exposure that might occur after a nuclear incident. <
'/>"/>

SOURCE Avaxia Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
2. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis
3. Pinnacle Biologics, Inc. Announces the Successful Completion of a Financing Round
4. Dr. Lester Mandelker to Collaborate with Nuovo Biologics, LLC
5. Oncobiologics, Inc. to Unveil New Biologics Proof-of-Concept Engine at BIO International Convention
6. Reportlinker Adds Biotechnology Industry 2010 Yearbook - Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions
7. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
8. LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
9. Radius Closes $27.65 Million Second Tranche of Previously Announced Financing
10. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
11. VisionGate Closes $2 Million Financing and Announces Collaboration to Evaluate Its 3D Cell Imaging Platform for Early Lung Cancer Detection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... Mass. , July 14, 2014 Minerva ... the development of new therapies to treat neuropsychiatric diseases ... has been appointed vice president of finance and ... Mr. Ahlholm is a senior executive with more than ... at technology and life science companies. His background includes ...
(Date:7/14/2014)... Mateo, CA (PRWEB) July 14, 2014 ... CONNECT patient registry platform, announced that three ... muscular dystrophies; the Phelan-McDermid Syndrome International Registry; ... Nephrotic Syndrome—have been awarded contracts by the ... of the creation of a new health ...
(Date:7/13/2014)... 30 years ago of soccer-ball-shaped carbon molecules called buckyballs ... there appears to be a new ball on the ... Tsinghua University in China have shown that a cluster ... similar to a carbon buckyball. It,s the first experimental ... of speculationdoes indeed exist. , "This is the first ...
(Date:7/13/2014)... July 13, 2014 2014 Deep Research ... a professional and in-depth study on the current state ... , The report provides a basic overview of the ... market analysis and Chinese domestic market analysis are provided ... landscape of the market. A comparison between the international ...
Breaking Biology Technology:Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer 2PatientCrossroads Fuels Development of New National Clinical Research Network 2PatientCrossroads Fuels Development of New National Clinical Research Network 3Researchers discover boron 'buckyball' 2Researchers discover boron 'buckyball' 32014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 22014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 3
... 5 DURECT Corporation,(Nasdaq: DRRX ) announced today ... 31, 2007. Total revenues were $6.6 million for the,three ... for the same,period in 2006. Net loss for the ... to a net loss of $9.8 million for the ...
... ST. LOUIS, Feb. 5 Monsanto Company,s ... global commercial,business, and Carl Casale, executive vice ... in separate presentations at two,conferences later this ... an update on the company,s,business performance and ...
... BEIJING and CLAREMONT, Calif., Feb. 5 /Xinhua-PRNewswire-FirstCall/ ... Board: KWBT) reports,on a meeting between Kiwa ... and Dr.,Xiao-Dong Huang from the Department of ... the possibility of collaboration in research and,development ...
Cached Biology Technology:DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 2DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 3DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 4DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 5DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 6DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 7DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 8DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 9Kiwa Bio-Tech Products Group Discusses Cooperative Research With the University of Waterloo, Canada 2Kiwa Bio-Tech Products Group Discusses Cooperative Research With the University of Waterloo, Canada 3
(Date:7/14/2014)... than 140 years ago, Charles Darwin noticed something peculiar ... species are more tame, and they also tend to ... ears, patches of white fur, and more juvenile faces ... this pattern has proved elusive, but now, in a ... a new hypothesis has been proposed that could explain ...
(Date:7/14/2014)... at the University of East Anglia have shown how ... growth in cancer patients. , Research published today ... are responsible for the drug,s success in shrinking tumours. ... help develop a synthetic equivalent with anti-cancer properties. ... Complutense de Madridin, Spain. The team used samples of ...
(Date:7/14/2014)... researchers have developed a technology that could overcome ... fuel a fuel that could replace expensive ... technology is a novel catalyst that performs almost ... reactions, which use electric currents to split water ... is also far more efficient than less-expensive catalysts ...
Breaking Biology News(10 mins):Domestication syndrome: White patches, baby faces and tameness 2UEA research reveals how cannabis compound could slow tumour growth 2Rutgers chemists develop technology to produce clean-burning hydrogen fuel 2
... LA JOLLA, CA---- Researchers at the Salk Institute for Biological ... skin cells and turned them into induced pluripotent stem cells ... form any other cell or tissue in the body. ... Shinya Yamanaka at Kyoto University in Japan, and human iPSCs ...
... Calif.) It happens in military units, street gangs ... cultures, the rituals mark the transition from adolescence to ... given. With a long history of seemingly universal ... puzzle. Why have so many cultures incorporated it into ...
... market to treat leukemia reversed symptoms of colitis in lab ... the University of Alberta. Faculty of Medicine & Dentistry ... journal, PLOS ONE . His team ... role in the development of colitis. When this gene quits ...
Cached Biology News:Induced pluripotent stem cells reveal differences between humans and great apes 2Induced pluripotent stem cells reveal differences between humans and great apes 3UCSB anthropologist examines the motivating factors behind hazing 2UAlberta medical researchers discover potential new treatment for colitis 2UAlberta medical researchers discover potential new treatment for colitis 3
... system uses a burst of high-pressure ... acid-coated gold or tungsten microparticles to ... or organelles without dependence or interaction ... includes helium pressure regulator, solenoid, spacer ...
... system, 220-240 V, is used for ... The system includes the BioLogic LP ... MV-6 injection valve, proportioning valve or ... and fittings kit, column and conductivity ...
Sf21 Insect Cells (Frozen) in Max-XP Medium...
... have been developed for affinity capture ... variety of ProteinChip chemical surfaces allow ... their unique biochemical properties. Each chip ... sample comparison, and the chips are ...
Biology Products: